BeiGene, Ltd.
06160
2023 12 31
2023 12 31 2022
GAAP
2023 12 31 2022 12 31
10 73.7% 25 2022 12 31
935.2 74.5% 22
2023 12 31 2022 12 31
367.5 12.6% 3,286.6
2023 12 31 2022 12 31
11 56.0% 881.7
2023 12 31 0.65
2022 12 31 1.49 56.4%
1
12 31
2023 2022
3,171,800 3,869,564
4 11,473 196
5 2,600 665,251
6 358,027 173,168
7 416,122 282,346
12 243,392 216,553
4,203,414 5,207,078
9 1,324,154 845,946
8 95,207 109,960
10 57,138 40,616
12 125,362 175,690
1,601,861 1,172,212
5,805,275 6,379,290
13 315,111 294,781
12 693,731 467,352
3 – 213,861
11 22,951 25,189
8 21,950 24,041
3 68,004 114,335
14 688,366 328,969
1,810,113 1,468,528
2
12 31
2023 2022
14 197,618 209,148
3 300 42,026
8 22,251 34,517
11 16,494 15,996
3 170,662 179,625
12 50,510 46,095
457,835 527,407
2,267,948 1,995,935
23
0.0001
9,500,000,000 2023
2022 12 31
1,359,513,224
1,356,140,180 135 135
11,598,688 11,540,979
19 (99,446) (77,417)
(7,962,050) (7,080,342)
3,537,327 4,383,355
5,805,275 6,379,290
3
12 31
2023 2022
15 2,189,852 1,254,612
3 268,927 161,309
2,458,779 1,415,921
379,920 286,475
2,078,859 1,129,446
1,778,594 1,640,508
1,504,501 1,277,852
10 3,500 751
3,286,595 2,919,111
(1,207,736) (1,789,665)
74,009 52,480
5 307,891 (223,852)
(825,836) (1,961,037)
11 55,872 42,778
(881,708) (2,003,815)
17 (0.65) (1.49)
17 1,357,034,547 1,340,729,572
(8.45) (19.43)
104,387,273 103,133,044
4
12 31
2023 2022
(881,708) (2,003,815)
19 (25,464) (90,421)
22 (5,611) 365
19 9,046 (5,311)
(903,737) (2,099,182)
5
12 31
2023 2022
(881,708) (2,003,815)
87,675 66,278
18 367,618 303,162
3 46,800 68,665
3 (55,294) (96,402)
5 16,221 21,996
689 2,059
20 (362,917) –
(5,998) 9,047
(188,306) 304,112
(140,948) (56,689)
12,120 (3,282)
21,484 (4,352)
180,111 45,627
(255,587) (151,816)
587 (1,209)
(1,157,453) (1,496,619)
(561,896) (325,434)
(2,075) (1,485)
673,240 1,563,618
(15,000) (143,665)
10 (19,365) –
5 (14,900) (15,911)
60,004 1,077,123
6
12 31
2023 2022
14 22,502 37,372
14 661,530 313,774
14 (323,266) (417,081)
55,712 46,964
416,478 (18,971)
(8,082) (69,383)
(689,053) (507,850)
3,875,037 4,382,887
3,185,984 3,875,037
3,171,800 3,869,564
11,473 196
2,711 5,277
56,003 29,500
19,753 25,169
91,804 95,346
31,800 –
7
2021 12 31 1,334,804,281 133 11,191,007 17,950 (5,076,527) 6,132,563
– – (152) – – (152)
1,375,621 – – – – –
19,960,278 2 46,962 – – 46,964
– – 303,162 – – 303,162
– – – (95,367) – (95,367)
– – – – (2,003,815) (2,003,815)
2022 12 31 1,356,140,180 135 11,540,979 (77,417) (7,080,342) 4,383,355
84,227 – – – – –
26,561,925 2 53,006 – – 53,008
(23,273,108) (2) (362,915) – – (362,917)
– – 367,618 – – 367,618
– – – (22,029) – (22,029)
– – – – (881,708) (881,708)
2023 12 31 1,359,513,224 135 11,598,688 (99,446) (7,962,050) 3,537,327
8
1.
2023 25 2022 10
11
3
(BTK)
PD-1
PARP1 PARP2
14
CRO
3,000 CRO 130
45 22,000
40
CMO
2010 10,000
9
2023 12 31
* 100%
2,722,787,023
* 100%
14,530,380,600
* 100%
1,434,344,311
* 100%
4,273,218,389
* 1,000,000 100%
* 100%
620,000,000
BeiGene USA, Inc 1 100%
BeiGene USA
BeiGene AUS Pty Ltd 56,947,230 100%
BeiGene Australia
BeiGene Switzerland GmbH 20,000 100%
BeiGene Switzerland
BeiGene Hopewell Urban Renewal, 507,943,128 100%
LLC
*
10
2.
2023 11 2023-07 280
2023 12 15 2024 12 15
2023 12 2023-09 740
(1)
(2)
5%
(3)
2024 12 15
11
3.
2023 12 31
2023 2022 12 31
12 31
2023 2022
79,431 46,822
104,477 104,994
71,980 –
13,039 9,493
268,927 161,309
12
2021 1
650,000,000
1,300,000,000
250,000,000
606
(1)
(2)
(3)
606
650,000,000
484,646,000 165,354,000
13
2021 12 31
2021 12 31
2023 9
2023 9
2023 2022 12 31
12 31
2023 2022
72,278 39,655
(1)
5,067 9,493
77,345 49,148
(1)
2021 12
TIGIT
2022
2022 1 300,000,000
2023 2023 2023
600,000,000 700,000,000
745,000,000
1,150,000,000
50%
25%
14
606
(1)
(2)
(3) (4)
300,000,000
(i)
(ii)
71,980,000 213,450,000
14,570,000
2023 7
15
2023 2022 12 31
12 31
2023 2022
7,153 7,167
104,477 104,994
71,980 –
(2)
8,859 –
192,469 112,161
(2)
2019 10
2020 1 2
2019 2020 11
2020 7
2020 12
R/R B
ALL 2021 7
R/R 2022 4
CD19 B
1,250,000,000
K R A S G12C
LUMAKRAS (sotorasib) AMG 510
AMG 510
16
2022 4 20
LUMAKRAS
2023 2
(i) 2023 1 1 2023 8 31 LUMAKRAS
(ii) LUMAKRAS
808
100%
2019 10 31
2020 1 2 174.85
15,895,001 20.5%
Anthony Hooper 2020
1 2023 1
132.74 2,109,902,000
601,857,000
2,779,241,000 2,162,407,000
616,834,000
17
2023 2022 12 31
12 31
2023 2022
53,314 98,955
55,294 96,402
108,608 195,357
2023
12 31
483,651
2023 2022 12 31
12 31
2023 2022
68,004 114,335
170,662 179,625
238,666 293,960
2023 12 31
12 31
2023 2022
8,358 5,898
(60,917) (54,865)
1,688 (1,216)
(50,871) (50,183)
2023 2022 12 31
108,691,000 71,720,000 2023 2022 12 31
55,474,000 54,064,000
18
2023 2022 12 31
12 31
2023 2022
46,800 68,665
– 5,500
24,365 –
71,165 74,165
2023 11
2 2024
1 30,000,000
1,300,000,000
2023 12 31
2022 12
LY01005 2022 12 48,665,000
30,000,000
2023 12 31 19,365,000
Shoreline Biosciences, Inc.
2021 6 Shoreline Biosciences Inc. Shoreline
Shoreline
Shoreline
Shoreline
Shoreline
Shoreline 2022 1 45,000,000
2021 12 31
Shoreline 2024
19
2021 12
LBL-007 LAG-3
2022 1
30,000,000 742,000,000
2021 12 31
EUSA Pharma
2020 1 EUSA Pharma EUSA
β
EUSA
EUSA 40,000,000
120,000,000
2020 12 31 2021
EUSA
Assembly Biosciences, Inc.
2020 7 Assembly Biosciences, Inc. Assembly Assembly
Assembly ABI-H0731 ABI-H2158
ABI-H3733
Assembly
Assembly 40,000,000
503,750,000 Assembly
2020 12
31 2023 12 Assembly
2020 8
(BAT1706)
2020 9 10
2020 9 18
2020 10
20,000,000
145,000,000 2020 12
31 2021 11
2023 12 5,000,000
20
2023 2022 12 31
4.
2023 2022 12
31
12 31
2023 2022
11,473 196
2,711 5,277
14,184 5,473
2023 12 31
1,191,583,000
5.
2023 12 31
2,565 35 – 2,600
2,565 35 – 2,600
21
2022 12 31
674,262 – 9,011 665,251
674,262 – 9,011 665,251
2023 12 31 2023
12 31
2023 12 31
Leap Therapeutics, Inc.
2020 1 Leap Therapeutics, Inc. Leap
5,000,000 Leap B B
2020 3 Leap Leap
2021 9 Leap 7,250,000
Leap 2023 12 31 Leap
2.9%
4.7%
Leap
12 31
2023 2022
425 30,102
2023 2022 12 31
12 31
2023 2022
Leap 3,046 3,307
Leap 542 706
2023 2022 12 31
55,860,000 57,054,000
22
12 31
2023 2022
(6,448) 5,065
2023 2022 12 31 25,981,000
27,710,000
12 31
2023 2022
7,856 3,682
6.
12 31
2023 2022
360,053 173,379
(2,026) (211)
358,027 173,168
30 120
12 31
2023 2022
6 356,243 172,633
6 12 1,784 535
358,027 173,168
23
12 31
2023 2022
1 1 211 415
16 1,861 (219)
(43) –
(3) 15
12 31 2,026 211
7.
12 31
2023 2022
148,772 88,957
39,098 20,886
228,252 172,503
416,122 282,346
8.
50 36 30
12
12 31
2023 2022
25,978 25,938
6,101 6,834
1,683 1,299
33,762 34,071
24
12 31
2023 2022
43,490 56,008
51,717 53,952
95,207 109,960
21,950 24,041
22,251 34,517
44,201 58,558
2024 12 31 23,499
2025 12 31 14,148
2026 12 31 5,740
2027 12 31 3,155
2028 12 31 1,682
932
49,156
(4,955)
44,201
12 31
2023 2022
27,985 28,064
11,854 22,278
12 31
2023 2022
3 3
7.22% 5.76%
25
9.
12 31
2023 2022
65,485 65,485
205,349 158,908
60,124 53,786
231,656 222,448
186,856 175,679
83,281 47,483
832,751 723,789
(249,212) (171,470)
740,615 293,627
1,324,154 845,946
2023 2022 12 31
12 31
2023 2022
579,649 224,392
119,380 33,332
16,135 12,256
25,451 23,647
740,615 293,627
2023 2022 12 31 80,436,000 62,302,000
10.
2023 2022 12 31
2023 12 31 2022 12 31
64,274 (7,807) 56,467 41,235 (4,119) 37,116
8,987 (8,316) 671 8,316 (4,816) 3,500
73,261 (16,123) 57,138 49,551 (8,935) 40,616
26
12
12 31
2023 2022
3,739 3,225
3,500 751
7,239 3,976
2023 12 31
12 31
2024 4,776 224 5,000
2025 4,776 224 5,000
2026 4,776 223 4,999
2027 4,776 – 4,776
2028 4,776 – 4,776
2029 32,587 – 32,587
56,467 671 57,138
11.
12 31
2023 2022
117,446 67,744
(315,852) (583,610)
(627,430) (1,445,171)
(825,836) (1,961,037)
27
12 31
2023 2022
25,170 4,844
24,956 27,905
5,059 6,547
55,185 39,296
687 3,480
– 2
687 3,482
55,872 42,778
12 31
2023 2022
(825,836) (1,961,037)
21% 21%
(173,426) (411,818)
141,902 209,692
19,134 29,223
32,581 33,872
(3,464) 1,375
845,811 229,550
(704,928) –
(64,343) (42,844)
(37,395) (6,272)
55,872 42,778
(6.8)% (2.2)%
28
12 31
2023 2022
106,708 97,896
996,588 862,214
26,687 19,700
68,117 86,000
704,928 –
687,600 798,563
7,893 10,348
164,190 63,156
(7,735) (10,098)
2,754,976 1,927,779
(2,771,470) (1,943,775)
(16,494) (15,996)
2023 12 31
2023 2022 12 31
12 31
2023 2022
1 1 1,943,775 1,758,409
845,811 229,550
(18,116) (44,184)
12 31 2,771,470 1,943,775
2023 2022 12 31 5,945,753,000
5,077,247,000 2023 12 31 2024
2033 1,839,748,000 2025 2030
4,088,658,000 2,047,000 76,794,000
2036 2043 704,928,000
2028
29
2023 2022 12 31
12 31
2023 2022
1 1 11,555 9,925
2,709 1,630
12 31 14,264 11,555
2023 12 31 12
2023 2022
12 31
2023 12 31 2013 2023
2013 2023 2020 2023
2015 2023
2013 2023
2025
2023 12 31 3,092,000
0.01
2023 12 31
2,969,000
30
12.
12 31
2023 2022
60,476 71,488
37,320 20,478
36,124 22,777
1,735 3,039
8,872 3,664
42,066 58,950
56,799 36,157
243,392 216,553
12 31
2023 2022
4,144 22,025
(1)
18,122 48,642
2,546 804
8,195 7,054
2,711 5,277
89,644 91,779
– 109
125,362 175,690
(1)
31
12 31
2023 2022
217,803 184,775
162,969 139,168
87,572 51,806
30,083 18,815
139,936 41,817
55,368 30,971
693,731 467,352
12 31
2023 2022
34,204 38,176
14,995 7,760
1,127 –
184 159
50,510 46,095
13.
2023 2022 12 31
12 31
2023 2022
3 302,310 290,284
3 6 8,205 2,570
6 1 4,551 1,379
1 45 548
315,111 294,781
32
14.
2023 2022 12 31
12 31
2023 2022
2018 4 4 580,000 9 2027 4 4 (1) 14,089 100,000 7,250 50,000
2020 1 22 (2) 9 2029 1 20 (2) 8,856 62,857 1,450 10,000
2020 11 9 378,000 9 2029 11 8 (3) 5,636 40,000 5,437 37,500
2023 7 28 380,000 1 2024 12 25 (4) 300,000 2,129,321 – –
2023 12 20 150,000 1 2024 12 19 7.3% 150,000 1,064,660 – –
2020 9 24 200,000 (5) – – 150,000 1,034,554
2022 2 25 50,000 1 2023 2 25 2.2% – – 50,000 344,851
2023 6 5 400,000 1 2024 6 4 3.2% 56,356 400,000 – –
2023 5 4 340,000 1 2024 5 3 (6) 47,903 340,000 – –
2023 5 30 200,000 1 2024 5 29 2.8% 28,177 200,000 – –
2023 11 14 700,000 1 2024 11 21 2.9% 49,312 350,000 – –
(7) 28,037 199,000 114,832 792,000
688,366 4,885,838 328,969 2,268,905
2018 4 4 580,000 9 2027 4 4 (1) 59,174 420,000 75,395 520,000
2020 1 22 (2) 9 2029 1 20 (2) 37,638 267,143 47,847 330,000
2020 11 9 378,000 9 2029 11 8 (3) 42,337 300,500 49,369 340,500
2022 7 29 480,000 10 2032 7 28 (8) 58,469 415,000 36,537 252,000
197,618 1,402,643 209,148 1,442,500
1. 2023 12 31
4.5% 2023 12 31 6,987,000
50,000,000
2. 2020 1 22
1,100,000,000
2021 12 31
1,100,000,000 350,000,000 2023 12
31 4.1% 2023 12 31 1,422,000
10,000,000 2017 3 3
3. 2023 12 31
3.9%
2023 12 31 5,281,000 37,500,000
4. (SOFR) 2023 12
31 7.2%
33
5. 2020 9 200,000,000
120,000,000
80,000,000
2021 10 8
2021 10 8
2022 10 8 2022 9 30
2023 12 31
150,000,000
6. 2023 12
31 4.5%
7. 2023 12 31
875,000,000 2022 12 15
2024 5 24 2023 12 31 28,174,000
199,000,000 109,576,000 792,000,000 2023
12 31 3.2%
2024 5
8. 2022 7
480,000,000 2023
12 31 3.9%
2023 12 31 22,502,000 163,000,000
2023 12 31
2023 12 31
2024 12 31 688,366
2025 12 31 35,565
2026 12 31 46,279
2027 12 31 46,279
2028 12 31 25,146
44,349
885,984
2023 2022 12 31
20,800,000 21,699,000 16,571,000
2,594,000
34
15.
2023 2022 12 31
12 31
2023 2022
2,718,969 1,438,440
(529,117) (183,828)
2,189,852 1,254,612
2023 2022 12 31
12 31
2023 2022
1,290,396 564,651
536,620 422,885
76,018 79,049
92,828 63,398
56,547 38,124
54,342 36,107
39,799 13,696
13,960 15,213
6,668 5,460
22,674 16,029
2,189,852 1,254,612
2023 2022 12 31
12 31
2023 2022
1 1 41,817 59,639
529,117 183,828
(430,998) (201,650)
12 31 139,936 41,817
35
16.
12 31
2023 2022
379,920 286,475
9 80,436 62,302
1,778,594 1,640,508
8 25,978 25,938
10 7,239 3,976
1,120,403 1,000,890
18 367,588 303,162
62,092 50,358
1,550,083 1,354,410
64,760 233,812
6 1,861 (219)
2,964 1,140
(78,373) (74,234)
2023 2022 12 31 699,289,000 602,585,000
17.
12 31
2023 2022
(881,708) (2,003,815)
1,357,034,547 1,340,729,572
(0.65) (1.49)
2023 2022 12 31
2023 2022 12 31
36
18.
2016
2016 1 2016
2016 2016 2 65,029,595
2016 2011 2011
2016 2011
2023 12 31
2011 2016 5,166,822 2016
2017 1 1 (i)
(5%) (ii)
2018 1 1 29,603,616
2016 2018 8
2016
2018 12 2016
38,553,159
2020 6 2016 57,200,000
2030 4 13 2016
2023 12 31 2016 37,575,472
2016 2016
2016 66,300,000
2022 3 31 5% 2022 6 22
2018
2018 6 2018 2018
12,000,000
5635(c)(4)
5635(c)(4) 2018
2018
2016 2018 8
)
2018
2016 2018 2022 6 22
37
2018
2018 6 2018
3,500,000 2018 8
2018 12
3,855,315 7,355,315
6
15%
10%
1 2
2023 8 31 794,144 207.55 15.97 176.42 13.57 10,777
2023 2 28 930,582 171.10 13.16 145.44 11.19 10,414
2022 8 31 861,315 171.66 13.20 145.91 11.22 9,667
2022 2 28 667,160 210.52 16.19 178.94 13.76 9,183
2021 8 31 425,386 308.30 23.72 262.06 20.16 8,575
2021 2 26 436,124 236.30 18.18 200.86 15.45 6,738
1
2
2023 12 31 1,941,075
10
38
2011 2016 2018
2021 12 31 72,204,888 7.08
12,516,816 12.34 6.40
(5,898,217) 4.63 52,258
(2,296,634) 16.46
2022 12 31 76,526,853 7.85
9,817,925 16.37 8.14
(6,974,331) 4.54 92,051
(1,225,334) 17.60
2023 12 31 78,145,113 9.06 5.09 465,231
2023 12 31 59,221,091 6.93 3.91 452,750
2023 12 31 75,306,510 8.81 4.95 463,359
2023 12 31 16,085,419
96,053,000 2.5
2023 2022 12 31
61,121,000 62,548,000
39
12 31
2023 2022
7.26 ~ 10.72 5.51 ~ 9.04
3.4% ~ 4.6% 1.8% ~ 3.9%
2.8 2.8
58% ~ 60% 51% ~ 60%
0% 0%
10 10
2023 2022 12 31
2023 12 31
2016 2018
2021 12 31 36,082,982 18.33
38,707,669 12.46
(12,533,586) 16.37
(6,859,892) 16.72
2022 12 31 55,397,173 14.87
34,573,994 15.57
(17,862,598) 14.71
(5,707,546) 15.47
2023 12 31 66,401,023 15.22
2023 12 31 56,440,870 15.22
2 0 2 3 12 31
702,778,000 2.8
40
2023 2022 12 31
12 31
2023 2022
163,550 139,348
204,038 163,814
367,588 303,162
19.
2021 12 31 27,898 (3,700) (6,248) 17,950
(90,421) (5,311) (446) (96,178)
(1)
– – 811 811
(90,421) (5,311) 365 (95,367)
2022 12 31 (62,523) (9,011) (5,883) (77,417)
(25,464) 9,046 (6,422) (22,840)
(1)
– – 811 811
(25,464) 9,046 (5,611) (22,029)
2023 12 31 (87,987) 35 (11,494) (99,446)
(1)
41
20.
BMS
2023 8 1 BMS-Celgene
ABRAXANE
2017 2018
BMS-Celgene
2017 23,273,108
2023 12 31
2024 12 31
2023 8 15 362,917,000
2023 12 31
42
21.
10%
50%
2023 2022 12 31
10%
2023 2022 12 31
4,125,458,000 3,548,881,000
22.
2023 2022 12 31
94,358,000 83,860,000
401(k) 401(k) 401(k)
401(k) 2023 4%
2023 2022 12 31 401(k) 15,316,000
10,298,000
2023 2022 12 31
2,710,000 3,887,000
43
2023 2022
12 31 70,600,000 45,835,000
55,605,000 38,075,000
2021 12 31
19
2023 3,577,000
2023
12 31
2024 12 31 607
2025 12 31 214
2026 12 31 580
2027 12 31 985
2028 12 31 811
9,569
12,766
44
23.
2023 12 31 169,212,000 41,186,000
128,026,000 BMS
BMS
2023 12 31 333,498,000
1,250,000,000
2023 12 31 483,651,000
15,055,000 2023 12 31
8,905,000
(CRO)
45
24.
12 31
2023 2022
1,128,219 502,626
945,551 389,710
182,668 112,916
1,101,951 840,032
1,093,091 840,032
8,860 –
202,014 63,257
122,228 14,864
79,786 48,393
26,595 10,006
28,982 10,006
(2,387) –
2,458,779 1,415,921
46
25.
2023 12 31
(i) (iii)
(1,778,594) (31,745) 1,344 (1,808,995)
(1,504,501) (21,942) 1,659 (1,524,784)
74,009 – (3,082) 70,927
(825,836) (53,687) (79) (879,602)
(55,872) (15,000) – (70,872)
(881,708) (68,687) (79) (950,474)
2022 12 31
(i) (iii)
(1,640,508) (14,697) 471 (1,654,734)
(1,277,852) (19,296) 366 (1,296,782)
52,480 – (3,142) 49,338
(1,961,037) (33,993) (2,305) (1,997,335)
(42,778) 10,311 – (32,467)
(2,003,815) (23,682) (2,305) (2,029,802)
47
2023 12 31
(i) (ii) (iii)
95,207 – – (2,384) 92,823
5,805,275 – – (2,384) 5,802,891
11,598,688 68,687 – – 12,183,311
208,042* 307,894* –
(7,962,050) (68,687) – (79) (8,549,057)
(208,042)* (307,894)* (2,305)*
3,537,327 – – (2,384) 3,534,943
2022 12 31
(i) (ii) (iii)
109,960 – – (2,305) 107,655
6,379,290 – – (2,305) 6,376,985
11,540,979 33,993 – – 12,056,915
174,049* 307,894* –
(7,080,342) (33,993) – (2,305) (7,598,583)
10,311 – –
(184,360)* (307,894)* –
4,383,355 – – (2,305) 4,381,050
*
48
(i)
2023 12 31
53,687,000
2022 33,993,000
(ii)
2016 2
307,894,000
307,894,000
49
(iii)
2019 1 1
16
26.
2023 12 31 2022 12
31
50
(U.S. GAAP)
(U.S. GAAP) GAAP
GAAP
GAAP GAAP
GAAP
GAAP
GAAP
GAAP GAAP GAAP
GAAP
GAAP
GAAP
GAAP GAAP
GAAP GAAP
2023
2023
2023 25
73.7%
2023
13 128.5%
sonrotoclax
CLL 3 BTK CDAC R/R CLL
R/R MCL
51
2024 3 14 (FDA)
PD-(L)1
(ESCC)
2023 12 22 FDA
(R/R)
(CLL) 3 ALPINE (PFS)
2023 11 21
(IND) 2(CDK2)
2023 11 17 (EC)
R/R (FL)
2024 3,500 (BD)
52
13
1. 3,000
(CRO)
75%
2.
1,100
15
3
(R/R)
(CLL) (PFS) (ORR)
BCL-2 sonrotoclax BTK
(CDAC)BGB-16673
KRAS PRMT5 CDK4 CDK2
B7H3-ADC CEA-ADC B7H4-ADC MUC1 × CD16A
Claudin6 × CD3 CDAC
ADC mRNA
53
3.
29 37 5,000
800 ALPINE
BTK
2022 (ASH)
2023 12 (FDA)
R/R CLL 3 ALPINE
(PFS)
2023
2022
128.5%
sonrotoclax BCL2 BTK-CDAC CLL
B
PD-1
12
PD-1/PD-L1
2024 7
ESCC
KRAS PRMT5 CDK4 CDK2 B7H3-ADC CEA-
ADC B7H4-ADC MUC1 × CD16A Claudin6 × CD3
4. 3,700 500
2023 CLL (SLL)
17
BTK PD-1/PD-L1
65
2023
(EMA)
5.
2023 12 31 32
22
2024
54
2023 2022 12 31
2023 2022 12 31
12 31
2023 2022 %
2,189,852 1,254,612 935,240 74.5%
268,927 161,309 107,618 66.7%
2,458,779 1,415,921 1,042,858 73.7%
379,920 286,475 93,445 32.6%
2,078,859 1,129,446 949,413 84.1%
1,778,594 1,640,508 138,086 8.4%
1,504,501 1,277,852 226,649 17.7%
3,500 751 2,749 366.0%
3,286,595 2,919,111 367,484 12.6%
(1,207,736) (1,789,665) 581,929 (32.5)%
74,009 52,480 21,529 41.0%
307,891 (223,852) 531,743 (237.5)%
(825,836) (1,961,037) 1,135,201 (57.9)%
55,872 42,778 13,094 30.6%
(881,708) (2,003,815) 1,122,107 (56.0)%
55
2022 12 31 14 2023 12 31
10 25
2023 2022 12 31
12 31
2023 2022 %
2,189,852 1,254,612 935,240 74.5%
71,980 – 71,980
79,431 46,822 32,609 69.6%
104,477 104,994 (517) (0.5)%
13,039 9,493 3,546 37.4%
268,927 161,309 107,618 66.7%
2,458,779 1,415,921 1,042,858 73.7%
1
12 31
2023 % 2022 %
1,128,219 45.9% 502,626 35.5%
945,551 38.5% 389,710 27.5%
182,668 7.4% 112,916 8.0%
1,101,951 44.8% 840,032 59.3%
1,093,091 44.5% 840,032 59.3%
8,860 0.3% – %
202,014 8.2% 63,257 4.5%
122,228 5.0% 14,864 1.0%
79,786 3.2% 48,393 3.5%
26,595 1.1% 10,006 0.7%
28,982 1.2% 10,006 0.7%
(2,387) (0.1)% – %
2,458,779 100.0% 1,415,921 100.0%
1
56
12 31
2023 2022 %
1,290,396 564,651 725,745 128.5%
536,620 422,885 113,735 26.9%
76,018 79,049 (3,031) (3.8)%
92,828 63,398 29,430 46.4%
56,547 38,124 18,423 48.3%
54,342 36,107 18,235 50.5%
13,960 15,213 (1,253) (8.2)%
39,799 13,696 26,103 190.6%
6,668 5,460 1,208 22.1%
22,674 16,029 6,645 41.5%
2,189,852 1,254,612 935,240 74.5%
2023 12 31 22 13
2023 12 31
13
128.5% 2023 12 31
9.456
3.897 142.6%
CLL SLL 2023 12
31
1.938 28.9%
2023 12 31
1.222 2,880 722.3%
194.8% CLL SLL WM
2023 12 31
5.366
26.9% 2023 12 31
2023
1,320 2023 3 2024 1
57
2023 12 31 2.689
2023
2023 12 31
7,940
1.045
7,200 1,300
2022 12 31 1.613
2022 12 31
4,680
1.05 950
3
2024 12 31
2022 12 31 2.865 2023 12 31
3.799
2023 12 31 18
82.7% 2022 12 31 10
77.2%
58
2022 12 31 16 1.381
8.4% 2023 12 31 18 2023
2022 12 31
12 31
2023 2022 %
551,417 469,497 81,920 17.4%
46,800 68,665 (21,865) (31.8)%
1
53,315 98,955 (45,640) (46.1)%
651,532 637,117 14,415 2.3%
1,127,062 1,003,391 123,671 12.3%
1,778,594 1,640,508 138,086 8.4%
2
1,558,960 1,474,919 84,041 5.7%
1. 2023 12 31 1.086
5,330 5,530
2.
GAAP
GAAP
2023 12 31
Sonrotoclax(BGB-11417)
2022 12 31 10 1.237
12.3% 11
59
12 31
2023 2022 %
1,504,501 1,277,852 226,649 17.7%
1
1,284,689 1,077,977 206,712 19.2%
1.
GAAP GAAP
2022 12 31 13 2.266
17.7% 2023 12 31 15
2022 12 31 5,250 2,150
41.0% 2023 12 31 7,400
2023 12 31 3.079
BMS 3.629
2022 12 31 2.239
2023 12 31 5,590 2022 12 31
4,280 2023 12 31
174
60
2021 12
BEPS
GAAP
12 31
2023 2022
GAAP
GAAP 379,920 286,475
8,578 –
3,739 3,225
367,603 283,250
GAAP
GAAP 1,778,594 1,640,508
163,550 139,348
56,084 26,241
1,558,960 1,474,919
GAAP
GAAP 1,504,501 1,277,852
204,038 163,814
15,774 36,061
1,284,689 1,077,977
GAAP
GAAP 3,286,595 2,919,111
367,588 303,162
71,858 62,302
3,500 751
2,843,649 2,552,896
GAAP
GAAP (1,207,736) (1,789,665)
367,588 303,162
80,436 62,302
7,239 3,976
(752,473) (1,420,225)
61
2023 12 31
(i) 13 (ii) 130
18 (iii) 69.7
2022 12 31 173.2 106.8% 2023 12
31 358.0
2022 12 31 282.3 47.4% 2023 12 31
416.1
2022 12 31 216.6 12.4%
2023 12 31 243.4 (i) (ii)
2022 12 31 845.9 56.5% 2023 12
31 1,324.2
62
2023 2022 12 31
315.1 294.8
12 31
2023 2022
3 302,310 290,284
3 6 8,205 2,570
6 1 4,551 1,379
1 45 548
315,111 294,781
2023 2022 12 31
12 31
2023 2022
217,803 184,775
162,969 139,168
87,572 51,806
30,083 18,815
139,936 41,817
55,368 30,971
693,731 467,352
2022 12 31 467.4 48.4%
2023 12 31 693.7 (i)
(ii)
(iii)
2022 12 31 5.381 2023 12 31
8.860 64.6%
63
2023 12 31
12 31
2023 2022
3,185,984 3,875,037
2,600 665,251
885,984 538,117
2023 2022 12 31
9 20 2023 12 31 80
2017 9
2023 12 31
12
2023 12 31
(BeiGene, Ltd.) 8.860
(BeiGene, Ltd.) 5.472
12
2021 12 15
PRC
192.60 391.68
115,055,260 34
217
2023 12 31 12
64
2023 2022 12 31
12 31
2023 2022
3,875,037 4,382,887
(1,157,453) (1,496,619)
60,004 1,077,123
416,478 (18,971)
(8,082) (69,383)
(689,053) (507,850)
3,185,984 3,875,037
2023 12 31 12
8.817 3.705 9,480
BMS
2022 12 31 15
20
2.239 3.748
1.324
65
2023 12 31 6,000
6.732 5.619 1,500
1,940 1,490
210
2022 12 31 11 16
3.254 1.437
1,590 150
2023 12 31 4.165
6.615
5,570 2,250
3.096 1,370
2024 6.884
2022 12 31 1,900
4.171 3.138
4,700
3,740
66
2023 12 31
49,156 23,499 25,657
169,212 140,775 28,437
885,984 688,366 197,618
32,101 8,939 23,162
483,651 137,809 345,842
8,905 2,213 6,692
14,995 3,577 11,418
333,498 333,498 –
1,977,502 1,338,676 638,826
2023 12 31 1.692
4,120 BMS
1.280 BMS
67
6.884 1.976
2023 12 31
14
12.5
2023 12 31
4.837
1,510 2023
12 31 890
2023 12 31
360
2023 12 31 3.335
42
7,520
2022 4 29 2023 12 31
5.024
68
2023 2022 12 31 32
39 1,420 550
260 7
100 2023 12 31
10 10
2023 12 31 5.741
2023 12 31 100
570
2023 2022 12 31 3.580 1.732
69
1994
PBOC
2005
2023
2022 12 31 2.8% 8.2%
70
2023 12 31
2023 12 31
2022 12 31 12.3% 25.0%
42
7,520
2022 4 29 2023 12 31
5.024
2023 12 31
2023 12 31
2023 12 31
2023 12 31 10,500
2022 12 31 9,000
2023 12 31 16
2022 14
71
2023 12 31 14.2 2022 12 31
5.5
200.4 2022 12 31 123.9
2023 12 31 2022 12 31
2023 12 31
2
C1
72
C.2.1
Ranjeev Krishana
3.21
D.3.3 D.3.7
Anthony C. Hooper 2023 4
17 Olivier Brandicourt Corazon (Corsee) D.
Sanders 2023 9 13 Anthony C. Hooper
Thomas Malley
Anthony C. Hooper 3.10(2)
3.21 Thomas Malley 2024 1 22
Thomas Malley
2024 1 23 Olivier Brandicourt
Malley Olivier Brandicourt
2024 1 23
73
3.25
E.1.2
Margaret Han Dugan
Ranjeev Krishana Margaret Han Dugan
3.27A B.3.1
Donald W. Glazer Michael Goller Anthony C. Hooper
2023 4 17 Alessandro Riva Donald
W. Glazer
C3
74
B.8
BMS-Celgene 23,273,108
2023 8 2 2023 11 1
13.51(B)(1)
13.51(B)(1)
Anthony C. Hooper 2023 4 17
2023 9 13
Thomas Malley 2023 9 13
2024 1 22
Olivier Brandicourt 2024 1 23
2024 3 19
75
2020 1 2
174.85 15,895,001
206,635,013
20.5% 2,779,241,000 (a) 2019 10
30 30
36% (b) 1.00 7.84 2019
10 31 26% (c)
2019 10 31 26%
2019 11 29
2023 12 31
2023
12 31
2022 2023
12 31 12 31
(%)
(a)
2,779,241 100% 2,080,068 2,229,632 549,609
(a)
12.5
2019 11 29
2026 2019 11 1 2019
12 9 2020 1 3
2020 9 24
20.6%
20.4% 75,000,000
76
90
2020 12 1
(a) 20%
(b) 60 (c)
2020 3 18 2020 9 25
2020 10 9
2021 9
165,529 2,151,877
50,000,000 2022 12 31 50,000,000
2021 12 15
2021 6 16 2021
192.60
234.89 391.68
115,055,260
3,392,616,000
(i) (ii)
(iii) (iv) (v)
2023 11 10
2020 11 16 2021 1 29 2021
4 20 2021 5 14 2021 6 1 2021 6 21 2021 6 28
2021 6 30 2021 7 9 2021 7 28 2021 10 15 2021
11 16 2021 11 23 2021 11 24 2021 11 29 2021
11 30 2021 12 2 2021 12 6 2021 12 7 2021 12 13
2021 12 21 2021 12 28 2022 4 29 2022 6 27
2022 8 30 2022 9 28 2023 4 25 2023 8 29 2023 11
13 2021 4 30
77
2023 12 31 137 80
2023 12 31
2023
2022 2023 12 31
12 31 12 31
13,245,940 4,499,849 7,169,470 6,076,470
467,700 376,601 434,188 33,512
150,000 153,451 153,451 (3,451)*
136,360 71,580 110,240 26,120
6,000,000 2,662,674 4,832,281 1,167,719
1,630,155 489,000 978,000 652,155
21,630,155 8,253,155 13,677,630 7,952,525
*
Anthony C. Hooper 2023 4 17
Olivier Brandicourt Corazon (Corsee) D. Sanders 2023 9 13
Anthony C. Hooper Thomas Malley
Thomas Malley 2024 1
22 Malley
2024 1 23 Olivier Brandicourt
Malley Olivier
Brandicourt 2024 1 23
2023 12 31
78
2023 12 31
2023 12 31
4400
730 730
Thomas Malley 2024 1 22
Thomas Malley
2024 1 23 Olivier Brandicourt
Thomas Malley Olivier
Brandicourt 2024 1 23
2024 3 19 Olivier Brandicourt
2024 1 23 2024 3 21
2023 12 31
79
2024 6 5
2024 4 19
2024
4 19
183 17
1712-1716
( www.hkexnews.hk )
( www.beigene.com ) 2023 12 31
2024 3 28
Olivier Brandicourt Margaret Han Dugan
Donald W. Glazer Michael Goller Anthony C. Hooper
Ranjeev Krishana Alessandro Riva Corazon (Corsee) D. Sanders
80